Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vandetanib alone and with chemotherapy in advanced NSCLC
NCT00290537Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2006
- Primary completion
- Apr 2008
- Countries
- 1
01
Overview
A Phase 2 trial of vandetanib in non-small cell lung cancer (NSCLC), sponsored by University of Texas MD Anderson Cancer Center. Started Jan 2006; status: terminated.
02
Drugs
vandetanib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00290537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00290537.